A multivariable Cox regression model was constructed using variables from the univariate analysis with a P≤0.1. There were 3 variables chosen to be included in the multivariable analysis. The stability of the analysis is borderline as it is generally accepted that for each variable in the analysis there should be 10 completed cases. This study had 18 death events and as such the analysis had 6 death events per variable (14). Calculations were made with STATISTICA 10 software. Results Participants From the

CRS and IPC database between 1994 and 2010, there were 11 patients with concomitant treatment of colorectal PM and HM in one procedure (CRS + hepatic Inhibitors,research,lifescience,medical resection). All of these patients were included in a PM/HM group. There were 140 remaining patients in the database after extracting the PM/HM

group. A selection process was conducted according to the methods section. Successful 1:2 matching was able to be performed according to HIPEC/SPIC, Inhibitors,research,lifescience,medical R1/R2 resection, and PCI (maximum point difference of 1) which amounted to 22 patients for the PM only group. Thus, the total study size was 33 patients. Clinical Inhibitors,research,lifescience,medical and surgical results Baseline clinical and surgical characteristics are presented in Tables 1,​,2.2. There was only one statistical difference which was the number of gastrointestinal Inhibitors,research,lifescience,medical resections. One other variable came close with a P-value of 0.06 concerning the greater

number of low differential tumours in the PM only group. The median number of SPIC treatments received was three in each group. All Inhibitors,research,lifescience,medical HIPEC treatments were completed as planned. The median number of HM lesions was 1. Three patients were treated for 2 lesions and one patient was treated for 3 lesions. Table 2 Surgical characteristics of colorectal PM/HM vs. PM only Preoperative chemotherapy was not significantly different but had a numerical Resminostat tendency (Table 1) while the adjuvant treatment did not differ at all. In the PM/HM group, there were 17 lines of systemic chemotherapy administered from diagnosis till CRS and IPC treatment including adjuvant treatment. There were 9 oxaliplatin based treatments, 6 irinotecan, and 2 5-FU. A combination with RAD001 solubility dmso biological therapy was given in 4 lines – 3 with bevacizumab and 1 with cetuximab. In the PM group, there were 23 lines of systemic chemotherapy during the same interval from diagnosis to adjuvant treatment. There were 14 oxaliplatin based treatments, 3 irinotecan, and 3 5-FU. There was missing data as to the drugs administered in 3 adjuvant treatments. A combination with biological therapy was given in 5 lines—3 with bevacizumab and 2 with cetuximab.